Dallah Healthcare Co. · TADAWUL:4004
Dallah Healthcare — Q1 2026 Earnings Presentation
28 slides from Dallah Healthcare's earnings presentation, 2026
Slide 1: Dallah Healthcare Co. Q1 2026
Dallah Healthcare Co. Q1 2026
Slide 2: Today's Speakers and Agenda
Today’s Speakers and Agenda 1. About us 2. Business Review 3. Financial Review Abdulaziz Alwohaibi Amine A.Hariz Omar Aljabari Saud Alraqraq Chief Operating Officer Chief Financial Officer Chief Commercial Officer Chief Corporate Affairs Officer
Slide 3: DHC's mission and vision guided by core values
DHC’s mission and vision … … guided by core values Mission Values To deliver excellent healthcare services Care and respect for our patients, which are consistent with our values and their needs and our society with the expectation of our patients, society, and partners Commitment to professional et
Slide 4: Dallah Healthcare Company offers an attractive investment opportunity
DHC has long been established in KSA and has shown year-on-year growth DHC has a strong product portfolio, consistently growing to address the evolving needs of patients Dallah Healthcare Company offers an DHC has numerous certifications positioning it at the forefront in terms of service excellence
Slide 5: History
Dallah Hospital- 1987 Al Nakheel Dallah Pharma 2002 Dallah Ob-gyne 2007 2012 DHC listing Dallah Pediatrics 2013 DMRF Afyaa Al Nakheel 2014 North clinics 2015 quite rapidly both organically and inorganically Dallah Hospital- 2018 Namar Dallah Al Nakheel Meras Arabia Medical west expansion 2019 Makkah
Slide 6: Portfolio of owned and invested companies
Dallah Health Company Portfolio Today, DHC owns and directly operates five categories of companies while also engaging in active management of portfolio investments Owned & operated by DHC Portfolio investments (ownership share, %) Hospitals Clinics Meras Clinics* (35.6%) Makkah Medical Center Home
Slide 7: DHC's longstanding presence in KSA and integrated portfolio of services
12 +2,210 Healthcare Facilities Beds DHC’s longstanding presence in KSA and integrated portfolio of services position it +20% 18% Patients Volume CAGR Net Profit as a leader in service FY21-25 CAGR FY21-25 excellence, quality, and patient safety 5 +207 Medical specialties & Cities around KSA special
Slide 8: Awards and Honours
ICHOM “Most Contributing Leading Hospital” The 1st Saudi hospital to receive the new version of ICHOM Accreditation By CHI “Ribbons 5” rating - The highest “Excellence in Patient Satisfaction” level of achievement in the Awards and Honours implementation of (PROMS).” by the Global Patient Experience
Slide 9: With +2,210 beds, DHC aims to further expand to meet future demand
Dallah Health Company Portfolio With +2,210 beds, DHC aims to further expand to meet future demand Combined current capacity at +2,210 beds across DHC's operational entities and investments Companies owned & operated by 540 300 475 274 180 4 3 DHC beds beds beds beds beds Location Cities Portfolio i
Slide 10: Future Projects
Dallah Health Company Portfolio Future Projects Dallah Alarid Hospital Wahat Al-Nakheel Real Estate Fund • Land: 45,000 sqm • DHC, Dallah Real Estate, Aljazira Capital, and Tatweer signed MoU to establish a • Built-up area: 87,300 sqm private real estate fund. • 250 Beds • An estimated value exceedi
Slide 11: DHC's presence across the Kingdom of Saudi Arabia
DHC's presence Al Khobar across the �)« Riyadh Al Hofouf Kingdom of ÷U�d�« ·uH�« Saudi Arabia Jeddah …b� Makkah W�dJ*« WJ� 10
Slide 12: The 1447 AH Hajj season
Dallah Health Company Portfolio The 1447 AH Hajj season 11
Slide 13: Array of medical services offered by DHC hospitals
Dallah Health Company Portfolio The array of medical services offered by DHC hospitals extends across various specialties, complemented by supplementary support services 207+ Medical specialties and subspecialties 4+ key Ancillary Services Medical services under the following therapy areas: Suppleme
Slide 14: Strong growth in patient volumes
Dallah Health Company Portfolio DHC has consistently delivered strong growth in patient volumes, reflecting its expanding healthcare platform. Patient volume (in 000s) CAGR 27.5% 20% 3,792 2,839 2,737 2,252 1,800 936 734 2021 2022 2023 2024 2025 Q1-2025 Q1-2026 • MMC and KHCC have been added startin
Slide 15: Certifications, accreditations and awards for service excellence and patient safety
Dallah Health Company Accreditations When addressing service excellence and patient safety, DHC has acquired several well-regarded certifications, accreditations, and awards One of the first hospitals in Dallah Hospital laboratory Dallah Hospitals catering Saudi Arabia awarded JCI certified by the C
Slide 16: DHC's Journey to Value-Based Healthcare
DHC’ Journey to Value-Based Healthcare DHC's is dedicated to leading the way in VBHC, ultimately delivering greater value and improved health outcomes for our patients Key initiatives: Pilot Programs Strategic Collaborations Future Focus • PROM & PREM with a Major Insurer • The Center for Value in H
Slide 17: Growth Strategy & Leadership: 5-year strategy
Dallah Health Company Growth Strategy & Leadership DHC's future growth is supported by its well-defined 5-year strategy anchored around a coherent direction for the diversified portfolio Deep-dive included in the next slides Operating companies Investments Become a one-stop shop for VIP/A privately
Slide 18: Becoming a 'one-stop high-end' service provider
Dallah Health Company Growth Strategy & Leadership To become a 'one-stop high-end' service provider, DHC will selectively specialize as well as expand into clinics, telemedicine, post-acute care and homecare Value One-stop-shop high-end provider First point of contact from the cradle to the grave Pr
Slide 19: Q1-2026 key consolidated financial results
Dallah Health Company Financial Performance Q1-2026 performance reflects seasonal factors and the absence of Q1-2025 non-recurring gains, while acquisitions continue to drive strong operational growth Key consolidated financial results (M SAR) Q1-2025 Q1-2026 Revenues 833 22% 1,013 1 EBITDA 232 (16%
Slide 20: Revenue growth supported by acquisitions
Dallah Health Company Financial Performance DHC sustained strong revenue growth momentum, supported by strategic expansion through acquisitions. Al-Khobar revenues increased 50% Year-on-Year Revenues (M SAR) CAGR 22% 18% 4,067 3,206 2,943 2,488 2,105 1,013 833 2021 2022 2023 2024 2025 Q1-2025 Q1-202
Slide 21: Gross profit and margin
Dallah Health Company Financial Performance Transitory pressure on gross margin due to acquisitions and seasonality, while the acquired entities are delivering encouraging operational performance with strong future improvement potential Gross Profit (M SAR) CAGR 12% 18% 1,600 1600 38% 36% 40% 40% 36
Slide 22: EBIT and EBIT margin
Dallah Health Company Financial Performance Reported EBIT margin declined 9pp, while adjusted EBIT margin decreased 3pp, reflecting seasonality and the impact of acquisitions. Margins of acquired assets have improved significantly and are expected to further improve going forward EBIT (M SAR) CAGR (
Slide 23: Adjusted EBITDA increased 7% in Q1-2026
Dallah Health Company Financial Performance Adjusted EBITDA increased by 7% in Q1-2026 compared to Q1-2025 to reach SAR 194m EBITDA (M SAR) CAGR (16%) 20% 1200 30% 1200 30% 1000 25% 23% 23% 21% 28% 21% 21% 1000 25% 922 800 20% 19% 751 800 20% 600 15% 630 600 15% 514 400 449 10% 400 10% 200 5% 200 5%
Slide 24: Net profit and margin
Dallah Health Company Financial Performance Net profit declined mainly due to one-off gain in Q1-2025. Despite the seasonality, the Group continued to deliver strong revenue and gross profit growth, supported by acquisitions, with earnings remaining in line with the budget Net Profit (M SAR) CAGR (4
Slide 25: Quarterly revenues
Dallah Health Company Financial Performance Q1-2026 recorded the fourth-highest quarterly revenue in the Group’s history Revenues (SAR M) 1,110 1,062 1,061 1,013 848 833 809 784 765 Q1-2024 Q2-2024 Q3-2024 Q4-2024 Q1-2025 Q2-2025 Q3-2025 Q4-2025 Q1-2026 24
Slide 26: Decreasing leverage and bonus shares
Dallah Health Company Financial Performance DHC pursues long-term target of decreasing leverage and announces bonus shares, with temporary debt surge solely linked to its growth strategy. Proceeds from the DMF transaction to be mostly used for settling debt Net debt-to-EBITDA and Gearing ratio 3.7x
Slide 27: Return on equity
Dallah Health Company Financial Performance DHC achieved a healthy return on equity in the past 5 years, averaging 14%, despite the surge in the equity base Return on Equity (M SAR) 14.2% 14.1% 14.3% 13.9% 13.9% 13.3% 12.2% 2021 2022 2023 2024 2025 Q1-2025 Q1-2026 26
Slide 28: Thank you
Thank you